The analysts offering Earnings Estimates for the company were believing that Cara Therapeutics Inc.
Taking a glance at past performance, we will examine different up or down moving trends about CARA. The stock went up 78.83% at some stage in past quarter. The consensus estimate for current quarter is $-0.53 and for the current fiscal year, the estimate is $-1.82.
Cara Therapeutics, Inc. (NASDAQ:CARA) shares typically trade an average volume of 1640.23 and institutions hold 53.20% of the total shares. Cara Therapeutics has a one year low of $4.35 and a one year high of $19.44.
Currently, the analyst consensus on Cara Therapeutics is Strong Buy and the average price target is $25, representing a 42.9% upside.
The Stock has Weekly volatility of 7.33% and monthly volatility of 7.32%.
Several institutional investors have recently made changes to their positions in the stock.
Cara Therapeutics Inc. (NASDAQ:CARA) is now showing its ROA (Return on Assets) of -46.6%. Presently, it has a Return on Equity (ROE) of -50.60% and Return on Investment (ROI) of -23.50%.
Cara Therapeutics Inc (NASDAQ:CARA) released its earnings results on Thursday.
In taking a look at technical levels, shares are trading 27.87% away from the 50 day simple moving average and 50.77% away from the 200 day simple moving average. Developed by J. Welles Wilder, ATR is an indicator that measures volatility. It may be used by market technicians to enter and exit trades, and it is a useful tool to add to a trading system. Current ratio which is the relationship between current assets and current liabilities, indicating the liquidity of a business is calculated as 11.30. In comparison, previous year the company earned revenue of $0 and had a GAAP net loss of $9.53 million. Russo covers the Healthcare sector, focusing on stocks such as Paratek Pharmaceuticals, Axsome Therapeutics Inc, and Flexion Therapeutics. (CARA) has received mean Analyst rating of 1.62 from polled analysts at Reuters 3 Month Ago. HC Wainwright set a $20.00 price objective on Cara Therapeutics and gave the stock a buy rating in a research note on Tuesday, November 22nd. 0 rated the company as a "Hold". This rating was issued on 10/13/16. (NASDAQ:CARA) could bring EPS of $-0.47/share. An earnings estimate is an analyst's estimate for a company's future quarterly or annual earnings. The company is set at a mean analysts' recommendation of 2.50.
At the time of writing, the stock was trading at $72.00.
Price Target is an important factor while doing analysis of a stock. Hence, it's not surprising that some companies are known for routinely beating earning projections. The 52-week low of the share price is at $4.35. For the quarter, shares are performing at 33.25%. The difference between Actual EPS and Estimated EPS was 0.05 Percent.